All In Biotech

Drug Trial Radar · NCT04956302

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

A Phase I Study of Panobinostat in Combination With Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Sep 27, 2021

Primary completion

Jun 16, 2022

Study completion Jun 16, 2022

Sponsor

Lead sponsor
Abdullah KhanAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the possible benefits and side effects of adding panobinostat to a combination of daratumumab, bortezomib and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Panobinostat may stop or slow multiple myeloma by blocking the growth of new blood vessels necessary for cancer growth. Giving panobinostat in combination with daratumumab, bortezomib and dexamethasone may work better in treating relapsed/refractory multiple myeloma.

Conditions

  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma

Interventions

  • BortezomibDrug

    Given SC

  • Daratumumab and Hyaluronidase-fihjDrug

    Given SC

  • DexamethasoneDrug

    Given PO or IV

  • Panobinostat LactateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase 2 doseTime frame: End of cycle 1 (1 cycle = 28 days)
  2. Incidence of adverse eventsTime frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.